Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease
Open Access
- 18 June 2024
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 96 (3) , 526-538
Abstract
Objective: To determine whether plasma phosphorylated‐Tau181 (pTau181) could be used as a diagnostic biomarker of concurrent Alzheimer's disease neuropathologic change (ADNC) or amyloidosis alone, as well as a prognostic, monitoring, and susceptibility/risk biomarker for clinical outcomes in Lewy body disease (LBD).Methods: We studied 565 participants: 94 LBD with normal cognition, 83 LBD with abnormal cognition, 114 with Alzheimer's disease, and 274 cognitively normal. Plasma pTau181 levels were measured with the Lumipulse G platform. Diagnostic accuracy for concurrent ADNC and amyloidosis was assessed with Receiver Operating Characteristic curves in a subset of participants with CSF pTau181/Aβ42, and CSF Aβ42/Aβ40 or amyloid‐β PET, respectively. Linear mixed effects models were used to examine the associations between baseline and longitudinal plasma pTau181 levels and clinical outcomes.Results: Plasma pTau181 predicted concurrent ADNC and amyloidosis in LBD with abnormal cognition with 87% and 72% accuracy, respectively. In LBD patients with abnormal cognition, higher baseline plasma pTau181 was associated with worse baseline MoCA and CDR‐SB, as well as accelerated decline in CDR‐SB. Additionally, in this group, rapid increases in plasma pTau181 over 3 years predicted a faster decline in CDR‐SB and memory. In LBD patients with normal cognition, there was no association between baseline or longitudinal plasma pTau181 levels and clinical outcomes; however, elevated pTau181 at baseline increased the risk of conversion to cognitive impairment.Interpretation: Our findings suggest that plasma pTau181 is a promising biomarker for concurrent ADNC and amyloidosis in LBD. Furthermore, plasma pTau181 holds potential as a prognostic, monitoring, and susceptibility/risk biomarker, predicting disease progression in LBD. ANN NEUROL 2024;96:526–538Keywords
All Related Versions
Funding Information
- National Institute of General Medical Sciences (K99AG071837)
- Alzheimer's Association (AARFD‐21‐849349)
- Michael J. Fox Foundation for Parkinson's Research (6440.0)
- National Alzheimer's Coordinating Center (P30‐AG066515)
- National Institute on Aging (AG047366, F32AG074625, R21AG058859, RF1AG077443)
- National Institute of Neurological Disorders and Stroke (NS062684, NS075097, R01NS115114)
This publication has 47 references indexed in Scilit:
- Illusory Responses across the Lewy Body Disease SpectrumAnnals of Neurology, 2023
- Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial designAlzheimer's & Dementia, 2022
- Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy BodiesJAMA Neurology, 2021
- Cognitive and Pathological Influences of Tau Pathology in Lewy Body DisordersAnnals of Neurology, 2018
- Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson'sDisease 2014 conferenceAnnals of Neurology, 2014
- Neuropathologic substrates of Parkinson disease dementiaAnnals of Neurology, 2012
- Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelinesMovement Disorders, 2012
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- Clinical diagnostic criteria for dementia associated with Parkinson's diseaseMovement Disorders, 2007